Celcuity(CELC.US) Director Sells US$5,488 in Common Stock
$Celcuity(CELC.US)$ Director Buller Richard E sold 350 shares of common stock on Jun 21, 2024 at an average price of $15.68 for a total value of $5,488.Source: Announcement What is statement of change
Celcuity To Participate in Jefferies Global Healthcare Conference
MINNEAPOLIS, June 03, 2024 (GLOBE NEWSWIRE) -- Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced its participation in the
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (GILD), Celcuity (CELC) and Icon (ICLR)
Celcuity Is Maintained at Buy by Needham
Celcuity Is Maintained at Buy by Needham
Express News | Celcuity Inc : Needham Cuts Target Price to $23.00 From $24.00
Celcuity Shares Rise 8.2% After $60 Million Offering Prices
By Chris Wack Celcuity shares were up 8.2% to $16.06 after the company priced an underwritten offering of 3.9 million shares at an offering price of $15.50 a share. All of the securities are to be s
Sector Update: Health Care Stocks Mixed Pre-Bell Thursday
Health care stocks were mixed pre-bell Thursday, with the Health Care Select Sector SPDR Fund (XLV) down 0.1% and the iShares Biotechnology ETF (IBB) gaining 0.2%. Sarepta Therapeutics (SRPT) shares a
Celcuity Plans Phase 3 Trial of Potential Breast Cancer Therapy, Receives Additional Term Loan
Celcuity (CELC) said Thursday it plans to launch a phase 3 clinical trial to evaluate gedatolisib in combination with other drugs as a first-line treatment for patients with HR+/HER2- advanced breast
Express News | Celcuity Inc: Gross Proceeds to Co From Offering Expected to Be $60.0 Mln
Express News | Celcuity Announces Pricing Of 3,871,000 Share Offering At $15.50/Share
Express News | Celcuity Announces Stock Offering at $15.50 per Share
Express News | Celcuity Announces Pricing of Underwritten Common Stock Offering
Express News | Celcuity Inc: Expects to Enroll First Patient in Q2 of 2025
Express News | Celcuity Inc: Received an Additional Term Loan of Approximately $62 Mln
Express News | Celcuity Inc. Announces Plan to Initiate a Phase 3 Clinical Trial for Gedatolisib as First-Line Treatment for Hr+/Her2- Advanced Breast Cancer and Secures Approximately $62 Million Debt Financing
Celcuity Is Maintained at Buy by Stifel
Celcuity Is Maintained at Buy by Stifel
Stifel Maintains Buy on Celcuity, Maintains $40 Price Target
Stifel analyst Bradley Canino maintains Celcuity (NASDAQ:CELC) with a Buy and maintains $40 price target.
Celcuity Coverage Assumed by Craig-Hallum at Buy
Celcuity Coverage Assumed by Craig-Hallum at Buy
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Celcuity (CELC) and 89bio (ETNB)
Express News | Celcuity Inc. : Craig-Hallum Raises Target Price to $27 From $25